“ All companies want investors who can bring more than cash. The partners and advisors at Tullis Health Investors have solid, long-term reputations, and John Tullis is a strong Surefire Medical board member and an invaluable resource in extending our business into China. ”
“ It is refreshing to work with Jim Tullis, who understands that the value of an organization is its leadership first, followed by the brands. His guidance comes with experience and deep knowledge of our industry. When things are going well, he is there to cheer us on, and when the inevitable bumps in the road are hit, he is the calming voice that finds solutions. He is the confidant that every CEO should have. ”
TG | Tullis Growth
Tullis Growth Fund was registered and launched in 2014. The fund's strategy and investment approach are based on the cumulative successes of our prior funds and a refinement of our strategy and focus for generating high value for our investors through health care investing.
OrthoSensor, Inc. develops and commercializes intelligent orthopedic devices and data services that provide quantitative feedback to surgeons and hospitals. The company’s intelligent orthopedic devices utilize advanced proprietary sensor and communications technologies, coupled with the company’s innovative software products, to facilitate evidence-based decisions in orthopedic surgery - with a goal of improving patient outcomes and reducing the cost of treating musculoskeletal disease.
TriSalus Life Sciences, previously known as Surefire Medical, is a privately held medical device firm focused on making the administration of cancer therapies safer and more effective for patients. The company created the Pressure-Enabled Drug Delivery™ (PEDD) technology and is committed to developing other applications of the technology for use in other solid tumors and for the administration of immuno-oncology (IO) therapies. TriSalus Life Sciences was founded in 2011.
Exagen Diagnostics, Inc. is a CAP-accredited and CLIA-certified specialty laboratory focused on the significant unmet need for accurate and timely diagnosis, prognosis and monitoring of autoimmune connective tissue diseases. Its groundbreaking solutions address the full continuum of care to help physicians deliver accurate, early diagnosis and optimized therapy.
Alphatec Holdings, Inc. (Nasdaq: ATEC), through its wholly-owned subsidiaries, Alphatec Spine, Inc. and SafeOp Surgical, Inc., is a medical device company that designs, develops and markets spinal fusion technology products and solutions for the treatment of spinal disorders associated with disease and degeneration, congenital deformities and trauma. The company's mission is to improve lives by providing innovative spine surgery solutions through the relentless pursuit of superior outcomes. ATEC markets its products in the U.S. via independent sales agents and a direct sales force.